Figure 2.
Figure 2. The frequency and effect sizes of the ERG risk allele and ALL features. Risk allele frequency (A) and OR (B) of rs2836365 were estimated for Hispanics with increasing levels of Native American genetic ancestry (10%-30%, 30%-50%, and 50%-100%). In the Forest plot (B), bars indicate 95% confidence intervals (CIs) and the gray vertical line indicates OR of 1. OR was estimated by logistical regression test. (C) Risk allele frequency of ERG SNP rs2836365 and ALL features. The analysis was restricted to the Hispanic Americans and EAs in the COG P9904/9905/9906 cohort because it represents a largely unselected and nationwide patient population. Variant frequency was indicated for ALL molecular subtype, sex, age at diagnosis, presenting white blood cell (WBC; 109 cell/L) count, and MRD at the end of remission induction. Logistic regression test with rs2836365 genotype adjusting for genetic ancestry (eg, ALL with vs without ETV6-RUNX1); *P < .05; ***P < .0005. Ctrls, controls; KMT2A-R, KMT2A rearrangement; MRD, minimal residual disease (at the end of induction therapy on day 29).

The frequency and effect sizes of the ERG risk allele and ALL features. Risk allele frequency (A) and OR (B) of rs2836365 were estimated for Hispanics with increasing levels of Native American genetic ancestry (10%-30%, 30%-50%, and 50%-100%). In the Forest plot (B), bars indicate 95% confidence intervals (CIs) and the gray vertical line indicates OR of 1. OR was estimated by logistical regression test. (C) Risk allele frequency of ERG SNP rs2836365 and ALL features. The analysis was restricted to the Hispanic Americans and EAs in the COG P9904/9905/9906 cohort because it represents a largely unselected and nationwide patient population. Variant frequency was indicated for ALL molecular subtype, sex, age at diagnosis, presenting white blood cell (WBC; 109 cell/L) count, and MRD at the end of remission induction. Logistic regression test with rs2836365 genotype adjusting for genetic ancestry (eg, ALL with vs without ETV6-RUNX1); *P < .05; ***P < .0005. Ctrls, controls; KMT2A-R, KMT2A rearrangement; MRD, minimal residual disease (at the end of induction therapy on day 29).

Close Modal

or Create an Account

Close Modal
Close Modal